Literature DB >> 27500766

Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension.

Yi Yan1, Xiao-Jian Wang2, Su-Qi Li2, Shu-Hui Yang2, Zi-Chao Lv2, Li-Ting Wang2, Yang-Yang He2, Xin Jiang2, Yong Wang3, Zhi-Cheng Jing4.   

Abstract

BACKGROUND: Aberrant transforming growth factor (TGF)-β signaling is involved in the pathogenesis of pulmonary arterial hypertension (PAH). We aimed to investigate the predictive value of the upstream ligand of TGF-β signaling (TGF-β1) on long-term mortality and the clinical characteristics of patients with idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH (HPAH). METHODS AND
RESULTS: Plasma TGF-β1 levels were measured in 151 IPAH and 65 HPAH patients retrospectively enrolled between January 2008 and March 2013, and compared to 61 healthy subjects. Data for mortality over time were obtained from hospital databases and from telephone follow-ups. The main outcome was all-cause death. Plasma TGF-β1 was significantly higher in IPAH/HPAH patients compared to control subjects (4.74 vs. 2.61ng/mL, respectively; P<0.001). Mean follow-up time was 3.4±1.8years, during which 86 patients died. ROC curves were utilized to determine TGF-β1 cutoff values. Compared to patients with TGF-β1 of <3.74ng/mL, heart function was significantly impaired (percentage of patients with WHO functional class III/IV, 51.4% vs. 65.5%, P=0.043) and mortality risk was elevated (P=0.009) for patients with TGF-β1>3.74ng/mL. However, the difference in mortality rate between patients with higher and lower TGF-β1 levels was only statistically significant for female patients (P=0.004), despite a similar trend for male patients. Multivariate analyses revealed that TGF-β1 (HR after log transformation base of 10: 2.623; 95%CI: 1.228-5.603; P=0.013) emerged as the independent predictor for all-cause mortality.
CONCLUSION: High circulating levels of TGF-β1 were an independent predictor of a poor outcome for IPAH/HPAH patients.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Pulmonary arterial hypertension; Survival; Transforming growth factor-β1

Mesh:

Substances:

Year:  2016        PMID: 27500766     DOI: 10.1016/j.ijcard.2016.07.192

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Decreased Endoglin expression in the pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia rat model.

Authors:  Julia Zimmer; Toshiaki Takahashi; Alejandro D Hofmann; Prem Puri
Journal:  Pediatr Surg Int       Date:  2016-11-07       Impact factor: 1.827

2.  Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Magdalena L Bochenek; Christiane Leidinger; Nico S Rosinus; Rajinikanth Gogiraju; Stefan Guth; Lukas Hobohm; Kerstin Jurk; Eckhard Mayer; Thomas Münzel; Mareike Lankeit; Markus Bosmann; Stavros Konstantinides; Katrin Schäfer
Journal:  Circ Res       Date:  2019-11-21       Impact factor: 17.367

3.  Pulmonary vascular involvement of IgG4-related disease: Case series with a PRISMA-compliant systemic review.

Authors:  Yong Zhou; Lingyan Shao; Wenjing Ruan; Joy Jin; Hangdi Xu; Kejing Ying; Xiaohong Wu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Identification of Potential Risk Genes and the Immune Landscape of Idiopathic Pulmonary Arterial Hypertension via Microarray Gene Expression Dataset Reanalysis.

Authors:  Jing Xu; Yicheng Yang; Yuejin Yang; Changming Xiong
Journal:  Genes (Basel)       Date:  2021-01-19       Impact factor: 4.096

Review 5.  Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling.

Authors:  Patrick Andre; Sachindra R Joshi; Steven D Briscoe; Mark J Alexander; Gang Li; Ravindra Kumar
Journal:  Front Med (Lausanne)       Date:  2022-01-24

6.  Implication of proliferation gene biomarkers in pulmonary hypertension.

Authors:  Yi Yan; Rong Jiang; Ping Yuan; Li Wen; Xiao-Bin Pang; Zhi-Cheng Jing; Yang-Yang He; Zhi-Yan Han
Journal:  Animal Model Exp Med       Date:  2021-11-22

Review 7.  Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Authors:  Benjamin J Dunmore; Rowena J Jones; Mark R Toshner; Paul D Upton; Nicholas W Morrell
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.